AU2017242541B2 - Mutant bordetella strains and methods for use - Google Patents

Mutant bordetella strains and methods for use Download PDF

Info

Publication number
AU2017242541B2
AU2017242541B2 AU2017242541A AU2017242541A AU2017242541B2 AU 2017242541 B2 AU2017242541 B2 AU 2017242541B2 AU 2017242541 A AU2017242541 A AU 2017242541A AU 2017242541 A AU2017242541 A AU 2017242541A AU 2017242541 B2 AU2017242541 B2 AU 2017242541B2
Authority
AU
Australia
Prior art keywords
subject
pertactin
deficient
respiratory tract
live attenuated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017242541A
Other languages
English (en)
Other versions
AU2017242541A1 (en
Inventor
Saliha AIT YAHIA SENDID
Camille Locht
Luis SOLANS
Anne TSICOPOULOS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur de Lille, Institut National de la Sante et de la Recherche Medicale INSERM, Institut Pasteur filed Critical Institut Pasteur de Lille
Publication of AU2017242541A1 publication Critical patent/AU2017242541A1/en
Application granted granted Critical
Publication of AU2017242541B2 publication Critical patent/AU2017242541B2/en
Priority to AU2022221438A priority Critical patent/AU2022221438B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Developmental Biology & Embryology (AREA)
AU2017242541A 2016-03-29 2017-03-29 Mutant bordetella strains and methods for use Active AU2017242541B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022221438A AU2022221438B2 (en) 2016-03-29 2022-08-24 Mutant bordetella strains and methods for use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662314843P 2016-03-29 2016-03-29
US62/314,843 2016-03-29
PCT/EP2017/057468 WO2017167834A1 (en) 2016-03-29 2017-03-29 Mutant bordetella strains and methods for use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022221438A Division AU2022221438B2 (en) 2016-03-29 2022-08-24 Mutant bordetella strains and methods for use

Publications (2)

Publication Number Publication Date
AU2017242541A1 AU2017242541A1 (en) 2018-10-11
AU2017242541B2 true AU2017242541B2 (en) 2022-06-30

Family

ID=58488973

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017242541A Active AU2017242541B2 (en) 2016-03-29 2017-03-29 Mutant bordetella strains and methods for use
AU2022221438A Active AU2022221438B2 (en) 2016-03-29 2022-08-24 Mutant bordetella strains and methods for use

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022221438A Active AU2022221438B2 (en) 2016-03-29 2022-08-24 Mutant bordetella strains and methods for use

Country Status (10)

Country Link
US (4) US10682377B2 (cg-RX-API-DMAC7.html)
EP (2) EP3436034B1 (cg-RX-API-DMAC7.html)
JP (1) JP6993984B2 (cg-RX-API-DMAC7.html)
CN (2) CN109069535B (cg-RX-API-DMAC7.html)
AU (2) AU2017242541B2 (cg-RX-API-DMAC7.html)
DK (1) DK3436034T3 (cg-RX-API-DMAC7.html)
ES (1) ES3027194T3 (cg-RX-API-DMAC7.html)
FI (1) FI3436034T3 (cg-RX-API-DMAC7.html)
SG (1) SG11201807783UA (cg-RX-API-DMAC7.html)
WO (1) WO2017167834A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2821830T3 (es) 2006-03-10 2021-04-27 Pasteur Institut Cepas de Bordetella vivas atenuadas como vacuna de dosis única contra la tos ferina
DK2424564T3 (en) 2009-04-28 2015-04-27 Inserm Inst Nat De La Santé Et De La Rech Médicale A vaccine for the prevention or treatment of a respiratory pathology allergendrevet
WO2017167834A1 (en) * 2016-03-29 2017-10-05 Institut Pasteur De Lille Mutant bordetella strains and methods for use
CN111278456B (zh) 2017-10-18 2024-08-09 里尔巴斯德研究所 表达血清3型菌毛的鲍特菌属菌株
EP4196155A4 (en) 2020-08-14 2025-03-19 Iliad Biotechnologies, LLC Lyophilized live bordetella vaccines
EP4247397A4 (en) 2020-11-17 2024-11-06 Iliad Biotechnologies, LLC TREATMENT AND PREVENTION OF NEUROPATHOLOGY ASSOCIATED WITH NEURODEGENERATIVE DISEASES
CA3261556A1 (en) 2022-07-22 2024-01-25 Institut National de la Santé et de la Recherche Médicale USE OF BORDETELLA STRAINS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
WO2025257397A1 (en) 2024-06-14 2025-12-18 Institut National de la Santé et de la Recherche Médicale Live attenuated bordetella vaccines capable of producing and secreting heterologous antigens

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010125014A1 (en) * 2009-04-28 2010-11-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
WO2013066272A1 (en) * 2011-11-02 2013-05-10 National University Of Singapore Effect of an attenuated bordetella strain against allergic disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713072B1 (en) 1987-11-02 2004-03-30 Chiron S.R.L. Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine
GB9115332D0 (en) * 1991-07-16 1991-08-28 Connaught Lab Manipulation of gene copy number in bordetella
FR2718750B1 (fr) 1994-04-19 1996-06-14 Pasteur Institut Protéines recombinantes de l'hémagglutinine filamenteuse de Bordetella, notamment, B. Pertussis, production et application à la production de protéines étrangères ou de principes actifs vaccinants.
DE69511392T2 (de) * 1994-04-28 2000-03-23 Takeda Chemical Industries, Ltd. Verfahren zur trennung von protektiven verbindungen aus bordetella pertussis
FR2754543B1 (fr) 1996-10-11 1998-12-31 Pasteur Institut Souche de bordetella deficiente dans la production de toxine et exprimant une proteine hydride, liposomes comprenant de la fha et leurs utilisations comme vaccins, et utilisation de la fha pour stimuler les reponses immunitaires
FR2840319B1 (fr) 2002-05-30 2004-08-20 Pasteur Institut Souches de bordetella rendues deficientes par attenuation genetique
AU2004229527B2 (en) 2003-04-11 2009-08-20 Medimmune, Llc Methods of preventing or treating respiratory conditions
ES2821830T3 (es) 2006-03-10 2021-04-27 Pasteur Institut Cepas de Bordetella vivas atenuadas como vacuna de dosis única contra la tos ferina
JP2010508860A (ja) 2006-11-15 2010-03-25 フォリア バイオテック インコーポレイテッド パパイヤモザイクウイルスに基づくインフルエンザ用ワクチン
WO2008118592A2 (en) 2007-02-23 2008-10-02 The Penn State Research Foundation Use of an avirulent bordetella mutant as a live vaccine vector
AU2008266910A1 (en) 2007-06-18 2008-12-24 Hemispherx Biopharma, Inc. Early intervention of viral infections with immune activators
WO2010146414A1 (en) 2009-06-15 2010-12-23 National University Of Singapore Influenza vaccine, composition, and methods of use
CN102793915B (zh) * 2012-07-25 2013-10-23 天津康希诺生物技术有限公司 一种无细胞百日咳疫苗的生产方法
EP2722338A1 (en) 2012-10-17 2014-04-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel recombinant Bordetella strains
WO2017167834A1 (en) * 2016-03-29 2017-10-05 Institut Pasteur De Lille Mutant bordetella strains and methods for use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010125014A1 (en) * 2009-04-28 2010-11-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
WO2013066272A1 (en) * 2011-11-02 2013-05-10 National University Of Singapore Effect of an attenuated bordetella strain against allergic disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A ZEDDEMAN ET AL: "INVESTIGATIONS INTO THE EMERGENCE OF PERTACTIN-DEFICIENT BORDETELLA PERTUSSIS ISOLATES IN SIX EUROPEAN COUNTRIES, 1996 TO 2012", EUROSURVEILLANCE, 2014,http://www.eurosurveillance.org/images/dynamic/EE/V19N33/art20881.pdf *
Hegerle et al. Vaccine 32: 6597-6600, Epub 11 October 2014 *
R THORSTENSSON ET AL, "A Phase I Clinical Study of a Live Attenuated Bordetella pertussis Vaccine - BPZE1; A Single Centre, Double-Blind, Placebo-Controlled, Dose-Escalating Study of BPZE1 Given Intranasally to Healthy...", PLOS ONE, 2014 *

Also Published As

Publication number Publication date
US20200323901A1 (en) 2020-10-15
ES3027194T3 (en) 2025-06-13
CN109069535B (zh) 2022-03-18
US20210290667A1 (en) 2021-09-23
US10682377B2 (en) 2020-06-16
AU2017242541A1 (en) 2018-10-11
EP4541809A3 (en) 2025-06-25
US20230381224A1 (en) 2023-11-30
WO2017167834A1 (en) 2017-10-05
CN109069535A (zh) 2018-12-21
US20170283890A1 (en) 2017-10-05
EP4541809A2 (en) 2025-04-23
AU2022221438B2 (en) 2024-10-03
US11065276B2 (en) 2021-07-20
JP2019513722A (ja) 2019-05-30
DK3436034T3 (da) 2025-05-12
EP3436034B1 (en) 2025-03-26
FI3436034T3 (fi) 2025-05-08
SG11201807783UA (en) 2018-10-30
EP3436034A1 (en) 2019-02-06
CN114767718A (zh) 2022-07-22
AU2022221438A1 (en) 2022-10-06
CA3018126A1 (en) 2017-10-05
JP6993984B2 (ja) 2022-02-03

Similar Documents

Publication Publication Date Title
AU2022221438B2 (en) Mutant bordetella strains and methods for use
Solans et al. The role of mucosal immunity in pertussis
JP2019513722A5 (cg-RX-API-DMAC7.html)
US12403188B2 (en) Bordetella strains expressing serotype 3 fimbriae
US20080254062A1 (en) Use of an avirulent bordetella mutant as a live vaccine vector
JP5745731B2 (ja) サルモネラワクチン
EP2453913A1 (en) A temperature sensitive vaccine strain of mycoplasma hyopneumoniae and uses thereof
WO2020049133A1 (en) Adenylate cyclase catalytic domain deficient bordetella strains
JP2001507568A (ja) ハイブリッドｆｈａを発現するボルデテラ株、リポソームおよびワクチン
CA3018126C (en) Mutant bordetella strains and methods of use
EP0535740B1 (en) Respiratory disease vaccine for cats
HK1262896B (zh) 突变型博德特氏菌属菌株及其使用方法
HK1262896A1 (en) Mutant bordetella strains and methods for use
Byeon et al. Generation of an attenuated Salmonella-delivery strains expressing adhesin and toxin antigens for progressive atrophic rhinitis, and evaluation of its immune responses in a murine model
CN116355827A (zh) 一种治疗结核病的重组卡介苗药物及其应用
HK40026630B (zh) 表达血清3型菌毛的鲍特菌属菌株
Verma et al. Comparative Study of the Adjuvanticity of FIA and Phosphatidylcholine Liposomes for Purified Mycobacterial RNA

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)